anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive a sham procedure. After unblinding takes place at 24 weeks, patients receive a Revita® DMR Treatment Paradigm 1. 48 weeks after initial sham (= 24 weeks after first DMR) patients may receive retreatment, if they want to.
Participants undergo two 120-minute hypoglycemic hyperinsulinemic clamp procedures (50 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of placebo - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
The present invention provides for a process for isolation of carotenoids crystals comprising drying a plant part to obtain a meal and extracting the meal with alcohol at a temperature in the range of about 50°C to 75°C to obtain oleoresin. The oleoresin is enriched with alcohol at a temperature in the range of about 25°C °C to 50°C and hydrolyzed with alcoholic alkali at a temperature in the range of about 70°C to 80°C to obtain reaction mixture. The carotenoids crystals are precipitated from the reaction mixture by adding hot water followed by filtering, washing and drying the carotenoids crystals. The present invention also relates to carotenoids crystals comprising lutein and zeaxanthin in the ratios of about 10:1 or 5:1 or 1:1 obtained by a process which comprises mixing an oleoresin rich in lutein and an oleoresin rich in zeaxanthin separately in a ratios ranging from about 80:20 (w/w) to 90:10 (w/w) or about 70:30 (w/w) to 30:70 (w/w) or about 10:90 (w/w) to 20:80 (w/w) and homogenized to obtain a mixed oleoresin. The mixed oleoresin is then hydrolyzed with an alcoholic alkali at a temperature of about 70°C to 80°C to obtain a reaction mixture. The carotenoids crystals are precipitated by adding hot water to the reaction mixture to form a precipitate. Carotenoids crystals having lutein and zeaxanthin in a weight ratio of about 10:1 or 5:1 or 1:1 respectively are obtained by filtering, washing and drying the precipitate.
The focus of this registration is Aim 2. Specific Aim 2 assesses the temporal order in which plasticity occurs in cortical motor and sensory brain areas during speech motor learning. Plasticity is assessed using measures of cortical excitability. Specifically, auditory, somatosensory and motor evoked potentials are elicited using single pulse TMS (motor), pure tone bursts (auditory), and mentalis nerve stimulation (somatosensory). Tests of cortical excitability are interleaved with trials involving speech motor adaptation. Cortical excitability is also measured using these same measures 24 hours after learning to assess retention.

The Speech Motor Learning and Retention Master Protocol is NCT06467292.
This will be a randomized, single site, controlled, pilot clinical trial, to evaluate the effects of in-office use of a closed-loop, allostatic, acoustic stimulation neurotechnology (High-resolution, relational, resonance-based, electroencephalic mirroring; HIRREM), compared with acoustic stimulation not linked to brainwaves (ambient nature sounds). Assuming a potential drop-out rate of 20%, up to 24 subjects will be enrolled to achieve a goal of having at least 20 subjects (10 per group) complete the study, per protocol. Patients who have blood pressures between 120-139 mm/Hg systolic, and/or 80-89 mm/Hg diastolic, as documented by their health care providers on two separate occasions, and no other exclusions, will be randomly assigned to receive either 8-16 sessions of either acoustic stimulation linked to brainwave activity (HCC), or acoustic stimulation not linked to brainwave activity (NCC), over a maximum of 4 weeks, with both groups continuing their current care throughout. There will be pre- and post-intervention data collection to include systolic and diastolic BP, and many secondary outcome measures including measures of autonomic cardiovascular regulation (continuous recording of BP and HR for calculation of measure of HRV and BRS), behavioral symptom outcomes (ISI, PSQI, ESS, CES-D, GAD-7, PCL-C, PSS), quality of life measure (QOLS), alcohol use (Audit C), and function performance measures (drop stick reaction testing, and grip strength). All measures will be collected at an enrollment visit (V1), and the intervention will begin 1-14 days later. BP and HR recordings will also be repeated prior to the start of the 7th session. Post-intervention data collections will be obtained at 1-7 days (V2), 4-6 weeks (V3, primary outcome), and 12-14 weeks (V4) following completion of the intervention. The primary outcome will be differential change in the systolic and diastolic BP from V1 to V3. Additional follow up (V4) will evaluate durability of effects. Following V4, those in the NCC group will be offered the opportunity to cross over to receive a course of HCC, and will continue to be followed for data collections at 1-7 days (V5), 4-6 weeks (V6), and 12-14 weeks (V7) after completing their crossover HCC sessions. Linear mixed models (LMMs) will be used to contrast longitudinal changes in systolic and diastolic blood pressure between the HCC and NCC groups. Mean contrasts will be used to compare the changes in blood pressures between groups from V1 to V3, our primary test of efficacy. Additional mean contrasts will be constructed to evaluate the consistency of any benefit of HIRREM through subsequent visits beyond V3. Comparisons of changes in all secondary outcomes will be assessed in a similar fashion.
PROBLEM TO BE SOLVED: To easily and precisely control the degree of aroma by diffusing the aromatic gas of aromatic material in an outer space through the side wall surface of hollow thread communicating the inside of container and the outer space. SOLUTION: A loop-shaped supporting member 20 is fixed on the outside surface of opening part 11 on a container 10. Besides, a hollow thread 30 is arranged inside a loop 21 of loop-shaped supporter 21, stuck and fixed by an adhesive material G. Such hollow threads 30 are curved in the form of hair pin, expose curved parts 31 outside the container 10 and arrange both terminal parts 32 inside the container. Since this hollow thread 30 has an axial hole, an aromatic material A in the container 10 is infiltrated into this axial hole because of capillary phenomenon. Then, since this hollow thread 30 is formed from a material with which aromatic gas can be diffused from the wall part of poly-propylene, etc., the aromatic material A in the axial hole is diffused through the fine holes on the side wall part of this hollow thread 30 into the atmosphere.  By changing the specification of hollow thread, the number and the quantity of exposure into the outer space, the degree of aroma can be controlled.
Store at 20° to 25°C (68° to 77°F); excursions are permitted from 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. PROTECT FROM FREEZING. Avoid excessive heat.

Do not remove unit from overwrap until ready to use. Do not use if overwrap has been previously opened or damaged. The overwrap is a moisture barrier. The inner bag maintains sterility of the solution. Tear overwrap at notch and remove premixed bag.
After the initial study visit, patients will immediately begin use of imiquimod cream at designated lesions (those with combined size \>50cm2) nightly for 5 consecutive days a week over 6 weeks. One week into the imiquimod treatment course, radiation therapy will be administered at Northwestern Medicine by radiation oncologists familiar with MF in 2 fractions of 4 Gy (total 8 Gy) over 2 days to the same designated lesions.
Arm 3: 7mCi (range 6-9 mCi) \[18F\]FP-R01-MG-F2 will be administered to the study participant. One vertex-to-thigh PET/CT scans to the center of the lung in the FOV will follow approximately 60 min post-injection.
OBJECTIVE: In this study, we present the results of biodemographic characteristics of households and associated factors with Down syndrome (DS) birth in Morocco.
METHODS: We conducted a retrospective survey between 2014 and 2017 addressed to 277 families with 925 siblings and at least one child with DS (279 with DS). The data are collected using a standardized questionnaire in Marrakech-Safi region. Data were entered and analyzed using the statistical program SPSS statistics software for Windows (version 20.0). χ2 and student t tests were used for testing statistical significance. Differences were considered significant when the p value <0.05.
RESULTS: The binary logistic regression analysis between DS and non-DS children in their biodemographic characteristics studied (sex, breastfeeding, duration of exclusive breastfeeding, birth weight, maternal age at birth, paternal age at birth, oral contraceptive use, duration of oral contraceptive use before pregnancy, child age, and rank of birth) showed that only maternal age and paternal age at birth, duration of exclusive breastfeeding, birth weight, and child age were associated with DS birth (odds ratio [OR] = 1.08; 95% Cl: 1.04-1.13, OR = 1.04; 95% Cl: 1.00-1.08, OR = 0.95; 95% Cl: 0.92-0.98, OR = 0.31; 95% Cl: 0.22-0.44, and OR = 0.90; 95% CI: 0.87-0.93, respectively). In the other hand, the comparison between some of socio- and biodemographic characteristics of households studied with data from National Population Survey and Family Health (2018) showed a higher level of education in women and men in our sample in comparison with the general population. Similar results were shown in proportion of men and women in paid employment, the proportion of smoking and alcohol consumption among men, and the rate of oral contraceptive use before pregnancy among women.
CONCLUSION: Highlighting the biodemographic characteristics of people with DS will help families to take good care of this group.
PURPOSE: To obtain the subject agent for external use lowered in side effects by reducing the containing amount of a synthetic adrenocortical hormones and containing a large amount of the other active ingredients, containing each specified amount of aspirin, a synthetic adrenocortical hormone and propylene glycol and a percutaneous absorbefacient. CONSTITUTION: This agent for external use contains (A) 1-80wt.% of aspirin or sodium cromoglycate, (B) 0.02-0.5wt.% of a synthetic adrenocortical hormone, (C) 1-30wt.% of propylene glycol, and (D) a percutaneous absorbefacient such as a higher fatty acid ester, amide linkage-contg. compound or a 2-10C divalent carboxylic acid (salt). The formulation of this agent is e.g. cream, paste, gel, ointment, milky lotion, lotion, solution or cataplasm. As for the dose of this agent, it is preferable that the daily amounts of the ingredients A and B to be used be 0.1-1g and 0.0001-0.005g, respectively.
Pregnant women are more susceptible to viral infections affecting the respiratory tract than non-pregnant women. Similar to non-pregnant patients, Covid-19 infection occurs with non-specific symptoms in pregnant patients. A computed tomography (CT) scan of lungs and several laboratory parameters are used to predict the prognosis of this infection, which starts with non-specific findings. Although it has been demonstrated that low-dose lung CT can be used safely in pregnant women, both clinicians and pregnant women tend to avoid tomography imaging due to its teratogenic effects

The CRP/albumin ratio (CAR) is a recently defined parameter which represents the ratio of a positive acute phase reactant to a negative acute phase reactant. It is an indicator of both the inflammatory state and the nutritional state, simultaneously. Recent studies have shown that the CRP/albumin ratio is a biomarker with prognostic value for various inflammatory disorders and serious diseases. With this study it is aimed to investigate the effect of CRP/albumin ratio in predicting the severity and prognosis of the disease in pregnant patients with more severe Covid-19 infection.
Blood samples will be obtained at admission, standard blood tests will be measured at the central laboratory whilst high sensitive troponin I at 0 and 1 hour will be analyzed using a POC instrument from Siemens Healthineers in the ED. ECG and HEART-score will be obtained in all patients, other clinical investigations will be ordered by the attending physician. If the cTnI concentration at admission and the 1-hour delta is below a pre-specified concentration, the HEART- score \< 4, and the ECG is non-ischemic the patients will be allocated to the rule-out of NSTEMI group and investigated according to the ED flow chart for non-coronary acute chest pain, in order to identify differential diagnosis. Finally, patients will be admitted or discharged based on the clinical judgement of the attending physician.
Men and women ages 18-65 with suspected acute head trauma within 24-72hrs. of presentation, scoring a 3-15 on initial evaluation on GCS scale.
The participants will be training two times per week in 10 weeks. Training will consist of a training programme consisting of strength training with rubber bands for hip and knee.
Methods of detecting adrenocorticotropin-secreting non-pituitary tumor are disclosed. The methods include administering an inhibitor of glucocorticoid receptor activity, such as mifepristone. Administering the inhibitor of glucocorticoid receptor activity increases the expression of somatostatin receptors in the adrenocorticotropin-secreting non-pituitary tumor. After administration of the inhibitor of glucocorticoid receptor activity, the subject is further administered an agent that specifically binds a somatostatin receptor, such as somatostatin receptor 2. The agent bound to the somatostatin receptor is detected, which detects the adrenocorticotropin-secreting non-pituitary tumor in the subject. Methods of treating or inhibiting, or both, an adrenocorticotropin-secreting non-pituitary tumor in a subject are disclosed. The methods include administering to the subject and the inhibitor of glucocorticoid receptor activity. After administration of the inhibitor of glucocorticoid receptor activity, the subject is administered a cytotoxic agent that specifically binds the somatostatin receptor.
NLRP3 inflammasome activation has emerged as a critical initiator of inflammatory response in ischemic retinopathy. Here, we identified the effect of a potent, selective NLRP3 inhibitor, MCC950, on autophagy and apoptosis under hypoxia. Neonatal mice were exposed to hyperoxia for 5 days to establish oxygen-induced retinopathy (OIR) model. Intravitreal injection of MCC950 was given, and then autophagy and apoptosis markers were assessed. Retinal autophagy, apoptosis, and related pathways were evaluated by western blot, immunofluorescent labeling, transmission electron microscopy, and TUNEL assay. Autophagic activity in Müller glia after NLRP3 inflammasome inhibition, together with its influence on photoreceptor death, was studied using western blot, immunofluorescence staining, mRFP-GFP-LC3 adenovirus transfection, cell viability, proliferation, and apoptosis assays. Results showed that activation of NLRP3 inflammasome in Müller glia was detected in OIR model. MCC950 could improve impaired retinal autophagic flux and attenuate retinal apoptosis while it regulated the retinal AMPK/mTOR/ULK-1 pathway. Suppressed autophagy and depressed proliferation capacity resulting from hypoxia was promoted after MCC950 treatment in Müller glia. Inhibition of AMPK and ULK-1 pathway significantly interfered with the MCC950-induced autophagy activity, indicating MCC950 positively modulated autophagy through AMPK/mTOR/ULK-1 pathway in Müller cells. Furthermore, blockage of autophagy in Müller glia significantly induced apoptosis in the cocultured 661W photoreceptor cells, whereas MCC950 markedly preserved the density of photoreceptor cells. These findings substantiated the therapeutic potential of MCC950 against impaired autophagy and subsequent apoptosis under hypoxia. Such protective effect might involve the modulation of AMPK/mTOR/ULK-1 pathway. Targeting NLRP3 inflammasome in Müller glia could be beneficial for photoreceptor survival under hypoxic conditions.
Identification of cancer drivers is a key challenge in explaining the mechanisms underlying cancer development and achieving accurate medicine. There are many ways to identify cancer drivers based on individual mutation sites or the entire gene. They ignore a large number of medium-sized functional elements. It is hypothesized that mutations occurring in different regions of the protein sequence have different effects on the progression of cancer. Here, we developed a new function-driven region (driver) identification method based on bayesian probability and multiple linear regression model to identify protein regions capable of regulating gene expression levels and having high functional impact potential. In combination with gene expression data and somatic mutation data, and in combination with functional impact scores (SIFT, PROVEAN) as a priori knowledge, we determined the most accurate cancer driver region for predicting gene expression levels. We evaluated the performance of the driver on BRCA and GBM datasets of TCGA. The results show that predriver recognizes a known cancer driver and outperforms the other three most advanced methods (edrriver, ActiveDriver and oncotricosvust).
Most group A streptococcus (GAS) disease occurs in childhood and the premise of this study is that with increasing age there is apparent clinical protection from GAS disease which is due to the acquisition of protective antibodies. The study therefore seeks to test the hypothesis that titers of anti-J8 antibodies will increase with increasing age. This study is part 5 of a series including Division of Microbiology and Infectious Diseases (DMID) protocols 05-0082, 05-0117, 05-0118, and 06-0081. Three hundred patients will be selected in 6 age groups with 50 patients in each group: 0-4 years of age, 5-14 years of age, 15-24 years of age, 25-34 years of age, 35-49 years of age, over 50 years of age. Participants will be recruited through the Colonial War Memorial (CWM) Hospital in Suva. Patients in the hospital who are having blood taken for reasons other than GAS disease will be approached and asked to participate in the study. These patients will include people who are donating blood to the blood collection service for CWM Hospital. In addition, it will include patients going to the operating room or patients having blood taken as an outpatient by the pathology blood collection service. Once informed consent is obtained, blood will be collected in a serum separator blood tube. The volume of blood required for age groups will vary: 3ml whole blood for those aged \<5 years, 5 mls for those aged 5-14 years, 7.5 mls for those aged greater than 14 years. Participants will be excluded if they have a history of serious GAS disease including acute rheumatic fever, acute post streptococcal glomerulonephritis, invasive disease, or rheumatic heart disease, or if they have had a sore throat or skin sores within the past 14 days. These participants will be excluded because it is not known if J8 titres may correlate with prior serious GAS diseases or if there is an acute J8 antibody response to recent GAS infection, and we are aiming to understand background titres of J8 antibodies in this population. In addition, these illnesses will affect the value of antistreptolysin O titre (ASOT) and anti-DNase-B to establish the upper limits of normal values. After blood is centrifuged it will be divided. Aliquots will be prepared for measurement of ASOT and anti-DNase B titers. Further aliquots will be stored in the laboratory and sent to Queensland Institute of Medical Research in batch for measurement of J8 antibodies.
Left ear transcutaneous vagus nerve stimulation will be applied to the participants in this group.A continuous electrical stimulation with a current frequency of 10 Heartz (Hz) with a current transit time of 300 μs was applied to the participants in both groups. The participants included in both groups were treated with taVNS with the "Vagustim" device for 20 minutes once a day and for a total of 10 sessions application was made.
A laminate comprises a water-permeable material with a low friction surface in the presence of water the material being bonded by a water dispersible pressure sensitive adhesive to a repulpable tape which has the water dispersible pressure sensitive adhesive on both its surfaces. A device for controlled and prolonged release of an anthelmintic in a miminant comprises a resilient and flexible ethylene-vinyl acetate copolymer core sheet sandwiched between a pair of coextensive resilient films of the copolymer, the core sheet contg. 10-75% by wt. of a water-soluble morantel salt dispersed in it. The device has one or more circular macroperforations 0.5-10 mm in dia. symmetrically distributed across its face and extending through the films and core sheet. The dia. and arrangements of the macroperforations in relation to the thickness of the core sheet is selected to expose sufficient interior edge area of the sheet to give the required morantel release rate. The device is constrained in a rolled configuration by constraining means which are releasable in the animal's rumen, i.e. a laminate.
BACKGROUND: The mitochondrial DNA (mtDNA) G10398A polymorphism has been associated with bipolar disorder (BD). It leads to an amino acid substitution within NADH dehydrogenase subunit, thereby altering the mitochondrial complex I function. This exploratory case-control study assesses the association of mtDNA G10398A with the risk of BD and its relationship to clinical variables in Indian patients.
METHODS: Cases met the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of BD-I in remission and had a family history of BD or recurrent unipolar disorder in biological relatives. The healthy controls (HC) had no known illness and were screened negative for Family Interview for Genetic Studies. Participants were assessed using Clinical Pro forma, NIMH-Life Chart Method and Alda lithium response scale. The mtDNA G10398A was assessed with real-time polymerase chain reaction using TaqMan assay.
RESULTS: A total of 82 participants were recruited across cases and controls, with 42 patients (50% with maternal history) and 40 healthy individuals with similar demographic profiles. The mean age of onset was 25.16 (standard deviation [SD] 7.6) years, with illness for 11.59 years (SD: 7.18). Allele A was found in 50% of cases compared to 32.5% HC (odds ratio = 2.08; 95% confidence interval [CI]: 0.85-5.09). Findings remain non-significant for patients with maternal mood disorders (allele A: 38.9%; 21/42). Cases with allele G had significantly higher body mass index (BMI) (P = 0.008) than those with allele A.
CONCLUSION: The study adds information on mtDNA 10398A amongst Indian patient samples and healthy individuals. No significant group difference was found with respect to mtDNA G10398A. The positive association of allele G with higher BMI has potential clinical relevance that can be further investigated in larger samples.